Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Esophageal Cancer|Lung Cancer|Stomach Cancer|Breast Cancer|Ovarian Cancer
Interventions: DRUG: CHP-HER2, CHP-NY-ESO-1
Sponsor: Ludwig Institute for Cancer Research
Collaborators: Mie University